Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASF vaccine
- Development stage
- Preclinical
- Lead developer
- Quratis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
The ASF vaccine is a veterinary vaccine candidate being developed by Quratis for the prevention of African Swine Fever (ASF). ASF is a highly contagious and lethal viral disease that affects both domestic and wild pigs, leading to significant economic losses in the agricultural sector. The vaccine is currently in the preclinical stage of development. Quratis aims to address the global need for an effective ASF vaccine, as the disease currently lacks widely available commercial preventative treatments.
- Other names
- African Swine Fever vaccine
02
Targets
ASFV (African swine fever virus)
Beyond the preview
Go deeper on ASF vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASF vaccine.